ENTRY       D03441                      Drug
NAME        Certolizumab pegol (USAN/INN);
            Certolizumab pegol (genetical recombination) (JAN);
            Cimzia (TN)
PRODUCT     CIMZIA (UCB)
FORMULA     C2115H3252N556O673S16
EXACT_MASS  47719.2868
MOL_WEIGHT  47748.8128
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG01936  TNF inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AB05
            Product: D03441<JP/US>
EFFICACY    Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody
  DISEASE   Crohn's disease [DS:H00286]
            Rheumatoid arthritis [DS:H00630]
            Psoriatic arthritis [DS:H01507]
            Ankylosing spondylitis [DS:H01674]
  TYPE      Monoclonal antibody
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  PATHWAY   hsa04010(7124)  MAPK signaling pathway
            hsa04060(7124)  Cytokine-cytokine receptor interaction
            hsa04210(7124)  Apoptosis
            hsa04350(7124)  TGF-beta signaling pathway
            hsa04380(7124)  Osteoclast differentiation
            hsa04612(7124)  Antigen processing and presentation
            hsa04620(7124)  Toll-like receptor signaling pathway
            hsa04650(7124)  Natural killer cell mediated cytotoxicity
            hsa04920(7124)  Adipocytokine signaling pathway
            hsa05323(7124)  Rheumatoid arthritis
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
                 L04AB05 Certolizumab pegol
                  D03441  Certolizumab pegol (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunosuppressants
               Tumor Necrosis Factor (TNF) Blockers
                Certolizumab Pegol
                 D03441  Certolizumab pegol (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D03441  Certolizumab pegol (USAN/INN); Certolizumab pegol (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG01936  TNF inhibitor
                D03441  Certolizumab pegol
            Drug classes [BR:br08332]
             Immunological agent
              DG01936  TNF inhibitor
               D03441  Certolizumab pegol
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D03441  Certolizumab pegol
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D03441  Certolizumab pegol (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03441
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03441
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03441
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03441
DBLINKS     CAS: 428863-50-7
            PubChem: 17397581
///
